Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis

Thrombosis Research

Volumn 106, Issue 4-5, 2002, Pages 179-181

  Heizmann, Marc ^a   Baerlocher, Gabriela M ^b   Steinmann, Felix ^c   Horber, Fritz F ^c   Wuillemin, Walter A ^a  

^a Division of Hematology   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c KLINIK HIRSLANDEN   (Switzerland)

Author keywords

Anti Xa activity; Nadroparin; Obese patients

Indexed keywords

NADROPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; MEASUREMENT; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; STANDARD; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MONITORING; KINETICS; VEIN THROMBOSIS;

ANTICOAGULANTS; AREA UNDER CURVE; BODY WEIGHT; CHROMOGENIC COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA; HUMANS; KINETICS; NADROPARIN; OBESITY; VENOUS THROMBOSIS;

EID: 0037092628     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00188-3     Document Type: Article

References (13)

1. Haas S., Flosbach C.W. Prevention of postoperative thromboembolism with enoxaparin in general surgery: a German multicenter trial. Semin. Thromb. Haemost. 19:1993;164-173.
2. Planes A., Vochelle N., Darmon J.Y., Fagola M., Bellaud M., Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 348:1996;224-228.
3. Bergqvist D., Benoni G., Björgell O., Fredin H., Helundh U., Nicolas S.et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N. Engl. J. Med. 335:1996;696-700.
4. Samama M.M., Cohen A.T., Darmon J.Y., DesJardins L., Eldor A., Janbon Ch.et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. J. Med. 341:1999;793-800.
5. Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson F.A.et al. Prevention of venous thromboembolism. Sixth ACCP consensus conference on antithrombotic therapy. Chest. 119:2001;132S-175S.
6. Weitz J.I. Low-molecular-weight heparins. N. Engl. J. Med. 337:1997;688-698.
7. Roland M., Tozer T.N., Clinical Pharmacokinetics. Concepts and Applications. Baltimore, Philadelphia, Hong Kong, London, Munich, Sydney, Tokyo: Lea and Febiger, Williams and Wilkins; 1995. p. 459-61.
8. Wilson S.J., Wilbur K., Burton E., Anderson D.R. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 31:2001;42-48.
9. Yee J.Y.V., Duffull S.B. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur. J. Clin. Pharmacol. 56:2000;293-297.
10. Handeland G.F., Abildgaard U., Holm H.A., Arnesen K.E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur. J. Clin. Pharmacol. 39:1990;107-112.
11. Collignon F., Frydman A., Caplain H., Ozoux L., Le Roux Y., Bouthier J.et al. Comparison of the pharmocokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 73:1995;630-640.
12. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 26:1996;24-38.
13. Leizorovicz A., Bara L., Samama M.M., Haugh M.C. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 23(Suppl. 1):1993;89-98.